Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Senior Vice President | September 17, 2013 | September 19, 2013 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date September 17, 2013 · Filed September 19, 2013
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 42,013 |
Ending reported balance
After 2013-09-17 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2013-09-17 · Grant · Acquired 22,833 · Balance 52,745 F1: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Row 2 · 2013-09-17 · Tax withholding · Disposed 10,732 · Balance 42,013 |
Filing footnotes · ownership attribution and instrument terms
F1: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 17, 2013 Filed Sep 19, 2013 22:37 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 10,732 | $35.01 | $375,727.32 |
DisclosureSEC source: 0001179110-13-014419 · edgar.xml · nonDerivative · entry 2 Forrest A. David · CIK 0001501589 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,013 Read SEC document |
| September 17, 2013 Filed Sep 19, 2013 22:37 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 22,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-014419 · edgar.xml · nonDerivative · entry 1 Forrest A. David · CIK 0001501589 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,745 F1 · shares: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 28, 2013 Filed Mar 2, 2013 00:41 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 8,563 | $34.26 | $293,368.38 |
DisclosureSEC source: 0001179110-13-003901 · edgar.xml · nonDerivative · entry 2 Forrest A. David · CIK 0001501589 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,912 Read SEC document |
| February 28, 2013 Filed Mar 2, 2013 00:41 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 16,466 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-003901 · edgar.xml · nonDerivative · entry 1 Forrest A. David · CIK 0001501589 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,475 F1 · shares: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 19, 2013 Filed Feb 20, 2013 23:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 746 | $35.08 | $26,169.68 |
DisclosureSEC source: 0001179110-13-003167 · edgar.xml · nonDerivative · entry 1 Forrest A. David · CIK 0001501589 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,318 Read SEC document |
| February 15, 2013 Filed Feb 20, 2013 23:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 165,000 | $0.00 Strike: $34.94 | $0.00 |
DisclosureSEC source: 0001179110-13-003167 · edgar.xml · derivative · entry 2 Forrest A. David · CIK 0001501589 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Common shares · 165,000 shares Expires 2023-02-14 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 55,000 on 2/15/2014, 55,000 on 2/15/2015, and 55,000 on 2/15/2016. Read SEC document |
| December 10, 2012 Filed Dec 12, 2012 22:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 13,867 | $0.00 Strike: $46.60 | $0.00 |
DisclosureSEC source: 0001179110-12-017433 · edgar.xml · derivative · entry 9 Forrest A. David · CIK 0001501589 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,733 Underlying: Common shares · 13,867 shares Expires 2021-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 10, 2012 Filed Dec 12, 2012 22:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 9,568 | $0.00 Strike: $51.74 | $0.00 |
DisclosureSEC source: 0001179110-12-017433 · edgar.xml · derivative · entry 8 Forrest A. David · CIK 0001501589 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,782 Underlying: Common shares · 9,568 shares Expires 2020-09-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 10, 2012 Filed Dec 12, 2012 22:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 6,200 | $0.00 Strike: $55.56 | $0.00 |
DisclosureSEC source: 0001179110-12-017433 · edgar.xml · derivative · entry 7 Forrest A. David · CIK 0001501589 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 6,200 shares Expires 2018-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 10, 2012 Filed Dec 12, 2012 22:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 5,700 | $0.00 Strike: $52.54 | $0.00 |
DisclosureSEC source: 0001179110-12-017433 · edgar.xml · derivative · entry 6 Forrest A. David · CIK 0001501589 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 5,700 shares Expires 2017-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 10, 2012 Filed Dec 12, 2012 22:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 47,286 | $65.10 | $3,078,318.60 |
DisclosureSEC source: 0001179110-12-017433 · edgar.xml · nonDerivative · entry 5 Forrest A. David · CIK 0001501589 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,064 Read SEC document |
| December 10, 2012 Filed Dec 12, 2012 22:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 13,867 | $46.60 | $646,202.20 |
DisclosureSEC source: 0001179110-12-017433 · edgar.xml · nonDerivative · entry 4 Forrest A. David · CIK 0001501589 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2012 Filed Dec 12, 2012 22:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 9,568 | $51.74 | $495,048.32 |
DisclosureSEC source: 0001179110-12-017433 · edgar.xml · nonDerivative · entry 3 Forrest A. David · CIK 0001501589 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2012 Filed Dec 12, 2012 22:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 6,200 | $55.56 | $344,472.00 |
DisclosureSEC source: 0001179110-12-017433 · edgar.xml · nonDerivative · entry 2 Forrest A. David · CIK 0001501589 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,915 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2012 Filed Dec 12, 2012 22:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 5,700 | $52.54 | $299,478.00 |
DisclosureSEC source: 0001179110-12-017433 · edgar.xml · nonDerivative · entry 1 Forrest A. David · CIK 0001501589 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,715 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2012 Filed Dec 21, 2012 19:45 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 352 | $64.59 | $22,735.68 |
DisclosureSEC source: 0001179110-12-018136 · edgar.xml · nonDerivative · entry 1 Forrest A. David · CIK 0001501589 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,755 F1 · balance_after: The reporting person's beneficial ownership includes the receipt of 43 shares pursuant to dividend reinvestment under the Abbott Laboratories 2009 Employee Stock Purchase Plan for Non-U.S. Employees. Read SEC document |
| September 17, 2012 Filed Sep 19, 2012 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 954 | $68.27 | $65,129.58 |
DisclosureSEC source: 0001179110-12-014278 · edgar.xml · nonDerivative · entry 2 Forrest A. David · CIK 0001501589 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,015 Read SEC document |
| September 17, 2012 Filed Sep 19, 2012 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-014278 · edgar.xml · nonDerivative · entry 1 Forrest A. David · CIK 0001501589 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,969 F1 · shares: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:19 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 5,131 | $57.04 | $292,672.24 |
DisclosureSEC source: 0001179110-12-004077 · edgar.xml · nonDerivative · entry 2 Forrest A. David · CIK 0001501589 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,136 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:19 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 9,867 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-004077 · edgar.xml · nonDerivative · entry 1 Forrest A. David · CIK 0001501589 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,267 F1 · shares: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 20, 2012 Filed Feb 22, 2012 22:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 711 | $56.36 | $40,071.96 |
DisclosureSEC source: 0001179110-12-003227 · edgar.xml · nonDerivative · entry 2 Forrest A. David · CIK 0001501589 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,400 Read SEC document |
| February 19, 2012 Filed Feb 22, 2012 22:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 746 | $56.36 | $42,044.56 |
DisclosureSEC source: 0001179110-12-003227 · edgar.xml · nonDerivative · entry 1 Forrest A. David · CIK 0001501589 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,111 Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 22:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 35,800 | $0.00 Strike: $56.26 | $0.00 |
DisclosureSEC source: 0001179110-12-003227 · edgar.xml · derivative · entry 3 Forrest A. David · CIK 0001501589 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,800 Underlying: Common shares · 35,800 shares Expires 2022-02-16 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 11,934 on 02/17/2013, 11,933 on 02/17/2014, and 11,933 on 02/17/2015. Read SEC document |
| September 17, 2011 Filed Sep 20, 2011 21:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 954 | $52.17 | $49,770.18 |
DisclosureSEC source: 0001179110-11-013423 · edgar.xml · nonDerivative · entry 2 Forrest A. David · CIK 0001501589 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,857 Read SEC document |
| September 17, 2011 Filed Sep 20, 2011 21:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,834 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-11-013423 · edgar.xml · nonDerivative · entry 1 Forrest A. David · CIK 0001501589 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,811 F1 · shares: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 20, 2011 Filed Feb 23, 2011 23:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 698 | $46.88 | $32,722.24 |
DisclosureSEC source: 0001179110-11-003284 · edgar.xml · nonDerivative · entry 2 Forrest A. David · CIK 0001501589 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,977 Read SEC document |
| February 19, 2011 Filed Feb 23, 2011 23:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 732 | $46.88 | $34,316.16 |
DisclosureSEC source: 0001179110-11-003284 · edgar.xml · nonDerivative · entry 1 Forrest A. David · CIK 0001501589 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,675 Read SEC document |
| February 18, 2011 Filed Feb 23, 2011 23:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 41,600 | $0.00 Strike: $46.60 | $0.00 |
DisclosureSEC source: 0001179110-11-003284 · edgar.xml · derivative · entry 3 Forrest A. David · CIK 0001501589 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,600 Underlying: Common shares · 41,600 shares Expires 2021-02-17 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 13,867 on 02/18/2012, 13,866 on 02/18/2013, and 13,867 on 02/18/2014. Read SEC document |
| February 15, 2011 Filed Feb 17, 2011 22:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 247 | $45.98 | $11,357.06 |
DisclosureSEC source: 0001179110-11-002925 · edgar.xml · nonDerivative · entry 1 Forrest A. David · CIK 0001501589 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,407 Read SEC document |
| September 28, 2010 Filed Sep 29, 2010 21:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,550 | $52.10 | $132,855.00 |
DisclosureSEC source: 0001179110-10-014378 · edgar.xml · nonDerivative · entry 1 Forrest A. David · CIK 0001501589 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,654 Read SEC document |
| September 17, 2010 Filed Sep 21, 2010 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 14,350 | $0.00 Strike: $51.74 | $0.00 |
DisclosureSEC source: 0001179110-10-014076 · edgar.xml · derivative · entry 2 Forrest A. David · CIK 0001501589 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,350 Underlying: Common shares · 14,350 shares Expires 2020-09-16 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 4,784 on 09/17/2011, 4,783 on 09/17/2012, and 4,783 on 09/17/2013. Read SEC document |
| September 17, 2010 Filed Sep 21, 2010 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 21,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-014076 · edgar.xml · nonDerivative · entry 1 Forrest A. David · CIK 0001501589 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,204 F1 · shares: These shares represent a retention award of restricted stock under the Abbott Laboratories 2009 Incentive Stock Program. These awards generally vest on the third anniversary of their grant date and include the right to have stock withheld for tax purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.